{"id":208284,"name":"GLAXOSMITHKLINE CONSUMER HEALTHCARE","slug":"glaxosmithkline-consumer-healthcare","state":"NJ","country":"United States of America","description":"Over the counter health care and consumer products company.","totalSpending":170000,"filings":6,"yearlySpending":[{"year":2021,"income":160000},{"year":2022,"income":10000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"TOB","display":"Tobacco"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"TRD","display":"Trade (domestic/foreign)"}],"firms":["FAEGRE DRINKER BIDDLE & REATH LLP"],"lobbyists":["ILISA HALPERN PAUL","JIM TWADDELL","LAURA HANEN","JENNIFER TAYLOR MCBRIDE"],"govEntities":["Agency for Healthcare Research & Quality (AHRQ)","Commerce, Dept of (DOC)","HOUSE OF REPRESENTATIVES","Intl Trade Administration (ITA)","SENATE","White House Office","Centers For Disease Control & Prevention (CDC)","Centers For Medicare and Medicaid Services (CMS)","Food & Drug Administration (FDA)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Tobacco cessation; Oral Health; Dietary Supplements; FDA OTC Policy; HSAs/FSAs; Budget: Appropriations for CDC oral health, chronic disease, and tobacco cessation programs.","Tobacco cessation; Oral Health; Dietary Supplements; FDA OTC Policy; HSAs/FSAs; Budget: Appropriations for CDC oral health, chronic disease, and tobacco cessation programs.","Tobacco cessation; Oral Health; Dietary Supplements; FDA OTC Policy; HSAs/FSAs; Budget: Appropriations for CDC oral health, chronic disease, and tobacco cessation programs.","Tobacco cessation; Oral Health; Dietary Supplements; FDA OTC Policy; HSAs/FSAs; Budget: Appropriations for CDC oral health, chronic disease, and tobacco cessation programs.","Dietary Supplement Eligible Expenses under HSAs/FSAs; H.R. 295, the Pandemic Healthcare Access Act; S. 128, the Primary Care Enhancement Act of 2021; S. 380, the Health Savings Act of 2021."]}